

## 17-AAG


Product Specifications	
<b>Catalog Number:</b>	HPK-101
<b>Molecular Formula:</b>	C <sub>31</sub> H <sub>43</sub> N <sub>3</sub> O <sub>8</sub>
<b>Application Notes:</b>	<i>The pharmacological and toxicological properties of this product have not been fully investigated. Exercise caution in use and handling. This product must not be used in humans.</i>
<b>Molecular Weight:</b>	585.7
<b>Purity:</b>	98% (TLC: 5% methanol/methylene chloride; R <sub>f</sub> =0.26)
<b>Format:</b>	Purple solid, soluble in DMSO (>20 mg/mL) and ethanol (10 mg/mL)
<b>Storage:</b>	Store at -20°C <i>Shipping conditions may differ from the recommended storage temperature</i>
<b>Related Products:</b>	
HPK-102	Geldanamycin
EKS-890	StressXpress Hsp90 (total) ELISA Kit
SPP-770	Hsp90 Native Protein
EKS-400A	Akt (PKB) Kinase Activity Kit
OSA-602	HIF-1α Monoclonal Antibody (Hα111a)

### Background:

17-AAG represents a less toxic and more stable analog of geldanamycin. An Hsp-90 inhibitor, 17-AAG displays a 100-fold higher affinity for Hsp-90 derived from tumor cells than that from normal cells<sup>1</sup>. 17-AAG inhibits Akt activation and expression in tumors, and synergizes with a number of antitumor agents such as taxol<sup>2</sup>, cisplatin<sup>3</sup>, and UCN-01<sup>4</sup>. 17-AAG causes the inactivation, destabilization and eventual degradation of HIF-1α<sup>5</sup>.

#### References:

1. Kamal, A. *et al.* (2003) *Nature* **425**, 407-410.
2. Solit, D.B. *et al.* (2003) *Cancer Res.* **63**, 2139-2144.
3. Vasilevskaya, I.A. *et al.* (2003) *Cancer Res.* **63**, 3241-3246.
4. Jia, W. *et al.* (2003) *Blood* **102**, 1824-1832.
5. Neckers, L. (2003) *Current Med Chem.* **10**, 733-739.



Structure